Page 7 - Galt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Galt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Galt Today - Breaking & Trending Today
StockNews.com began coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a report issued on Thursday. The firm issued a hold rating on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, August 15th. Get Our […] ....
StockNews.com initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note released on Wednesday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, August 15th. […] ....
StockNews.com assumed coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note published on Sunday. The brokerage issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, August 15th. Read Our […] ....
StockNews.com initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note published on Saturday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, August 15th. […] ....
Several brokerages have updated their recommendations and price targets on shares of Galectin Therapeutics (NASDAQ: GALT) in the last few weeks: 8/19/2023 – Galectin Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 8/15/2023 – Galectin Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They […] ....